ESGO-GCIG Rare Cancers Guidelines Project The European Society of Gynaecological Oncology (ESGO) and the Gynecologic Cancer Intergroup (GCIG) jointly developed clinically relevant and evidence-based algorithms for rare tumours, based on the previously elaborated initial project that was published in the Int J Gyn Cancer in 2014. The first guidelines draft was presented at the GCIG meeting in Chicago in June 2019 for comments and revision. After this meeting, both GCIG and ESGO societies circulated the different guidelines for definitive validation. The new guidelines covering the initial 10 cancer types were officially presented for the first time at the ESGO 21st European Congress on Gynaecological Oncology in November 2019 in Athens, Greece. The initial 10 tumour types include: Leiomyosarcomas, Carcinosarcoma, Sex Cord Tumours, Germ cell tumours, Cancerized teratoma, trophoblastic disease, ovarian clear cell carcinoma, ovarian mucinous carcinoma, ovarian low-grade serous carcinoma and small cell ovarian carcinoma hypercalcaemic. View the working groups. The Gynecologic Cancer Intergroup (GCIG) The GCIG is a collaboration of 29 international cooperative clinical trials groups from various countries who are committed to conduct high-quality randomized phase III trials among women with gynecologic cancers. Founded in 1993 and formalized in 1997, GCIG has developed from a small network of ovarian cancer researchers to a large international forum addressing multiple issues related to research in gynecologic cancers. Member groups of the GCIG have collaboratively conducted pivotal clinical trials in cancers of the ovary, endometrium, and cervix. For more information visit gcigtrials.org ESGO-GCIG Rare Cancers Working Groups ESGO would like to express its sincere gratitude to the international experts’ panel and reviewers, who devoted their time and effort to the ESGO-GCIG Rare Cancers guidelines and algorithms project of the first ten tumour types. Working Groups For each of these 10 tumour types, two chairs from different national cooperative groups were invited to co-ordinate the activity. Each of the 10 working groups included members from the GCIG groups a pathologist and a Methodologist, François Planchamp, France. The release of the Rare Cancers Algorithms Mobile App version in late 2020 will include the following tumour types prepared by the working groups below. Low Grade Serous Carcinoma GCIG Group Name Country GOG-F David Gershenson (coordinator) United States of America SGCTG Charlie Gourley (co-coordinator) United Kingdom COGI Ann Folkins United States of America ISGO Ora Rosengarten Israel GOTIC Masanori Yasuda Japan NOGGO Jalid Sehouli Germany AGO-AUST Thorsten Fischer Austria Br-GOG Rodrigo Fernandes Brazil CTI (ICORG) Donal Brennan Republic of Ireland CEEGOG David Cibula Czech Republic KGOG Miseon Kim Korea GINECO Fabrice Lecuru France AGO Pauline Wimberger Germany NCI US Elise Kohn United States of America SGCTG Patricia Roxburgh United Kingdom DGOG Christianne Lok The Netherlands Pathologist: Ciaran O’Riain (CTI) Republic of Ireland Ovarian Clear Cell Carcinoma GCIG Group Name Country GEICO Antonio Gonzales (coordinator) Spain GOTIC Keiichi Fujiwara (co-coordinator) Japan NOGGO Jacek Grabowski Germany CTI (ICORG) Paula Calvert Republic of Ireland MITO Sandro Pignata Italy NCI US Jung-min Lee United States of America AGO-AUST Christian Schauer Austria CEEGOG Lukas Rob Czech Republic AGO Ahmed El-Balat Germany GINECO Elsa Kalbacher France Br-GOG Mariana de Paiva Batista Brazil GOTIC Masashi Takano Japan G-GOC Rob Coleman United States of America KGOG Se Ik Kim Korea COGI Ann Folkins United States of America SGCTG Ros Glasspool United Kingdom DGOG Ingrid Boere The Netherlands KGOG Chong-Woo Yoo Korea Ovarian Sex-Cord Stromal Tumour Group Name Country GINECO Isabelle Ray-Coquard (coordinator) France AGO Philip Harter (co-coordinator) Germany DGOG Anneke. M Westermann The Netherlands NOGGO Sara Alavi Germany AGO Gunter Emons Germany MITO Gennaro Cormio Italy G-GOG Lois Ramondetta United States of America Br-GOG Giovanni Miglino Brazil SGCTG Nick Reed United Kingdom KGOG Byoung Soo Kwon Korea GOTIC Hitoshi Tsuda Japan GINECO Florence Joly France COGI Amer Karam United States of America NOGGO Wolfgang Schmitt Germany A-AGO Alain Zeimet Austria Ovarian Germ Cell Tumour GCIG Group Name Country MaNGO Nicoletta Colombo (coordinator) Italy NSGO Olesya Solheim (co-coordinator) Sweden AGO Annette Hasenburg Germany CEEGOG Helena Robova Czech Republic MITO Ugo de Giorgi Italy Br-GOG Maria Del Pilar Estevez Diz Brazil CTI (ICORG) Dearbhaile O'Donnell Ireland COGI Jonathan Berek United States of Amercia AGO-AUST Christian Marth Austria GINECO Frederic Selle France KGOG Seung-Hyuk shim Korea G-GOC Aaron Shafer United States of America SGCTG Ros Glasspool United Kingdom DGOG Ingrid Boere The Netherlands NOGGO Ioana Braicu Germany Pathologist: Sarit Aviel-Ronen (ISGO) Israel Ovarian Mucinous Carcinoma Group Name Country NCRI Jonathan Ledermann (coordinator) United Kingdom GOG-F Jubilee Brown (co-coordinator) United States of America DGOG Christianne Lok The Netherlands ISGO Dalia Tsoref Israel AGO-AUST Edgar Petru Austria G-GOC Michael Frumovitz United States of America KGOG Jung-Yun Lee Korea COGI Oliver Dorigo United States of America NCI US Elise Kohn United States of America NOGGO Pauline Wimberger Germany Br-GOG Francisco José C. Reis Brazil GINECO Sebastien Gouy France MITO Giorgio Valabrega Italy SGCTG Charlie Gourley United Kingdom AGO Frederik Marmé Germany Pathologist: Mojgan Devouassoux (GINECO) France ESGO Algorithms App Get started and download the ESGO Algorithms App! Available for iPhone, iPad and Android Devices. Not Yet a Certified Center? View the process! Directly to: Certified Centers Ovarian Cancer Surgery Webcasts Vulvar Cancer Management Guidelines ESGO Newsletter Get notified on all news and activities right in your mailbox. Sign-up Now! You May Also Like Advanced Ovarian Cancer Surgery Quality Indicators Read More Endometrial Cancer Guidelines Free Download Read More Cervical Cancer Management Latest Algorithms Read More Vulvar Cancer Guidelines Guidelines Read More